Loading data
CVMNYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development expense | 15.89 m USD | 18.16 m USD | 22.47 m USD | 25.36 m USD |
| Operating profit | -24.81 m USD | -26.35 m USD | -31.48 m USD | -36.06 m USD |
| Interest expense | 649 k USD | 746 k USD | 675.42 k USD | 1.08 m USD |
| Net income (reported basis) | -25.41 m USD | -26.92 m USD | -32.37 m USD | -36.7 m USD |
| Net income attributable to common shareholders | -25.41 m USD | -27.58 m USD | -32.37 m USD | -37.63 m USD |
| Basic earnings per share | — | — | — | -0.87 USD/share |
| Diluted earnings per share | -6.27 USD/share | -15.31 USD/share | -0.73 USD/share | -0.87 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.